About Neovacs
Neovacs is a company based in Paris (France) founded in 1993.. Neovacs has raised $17.91 million across 10 funding rounds from investors including Debiopharm, Kepler Cheuvreux and Maxim Group. Neovacs offers products and services including Kinoide. Neovacs operates in a competitive market with competitors including Biological E, Altimmune, Vaxart, Allergy Therapeutics and Medicago, among others.
- Headquarter Paris, France
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$17.91 M (USD)
in 10 rounds
-
Latest Funding Round
$2.56 M (USD), Post-IPO
Dec 08, 2018
-
Investors
Debiopharm
& 5 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Neovacs
Neovacs offers a comprehensive portfolio of products and services, including Kinoide. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Technology for immunotherapy targeting lupus and allergies.
Unlock access to complete
Unlock access to complete
Funding Insights of Neovacs
Neovacs has successfully raised a total of $17.91M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2.56 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Post-IPO — $2.6M
-
First Round
First Round
(18 Jul 2007)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2018 | Amount | Post-IPO - Neovacs | Valuation |
investors |
|
| Jun, 2017 | Amount | Post-IPO - Neovacs | Valuation |
investors |
|
| Jun, 2016 | Amount | Post-IPO - Neovacs | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Neovacs
Neovacs has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Debiopharm, Kepler Cheuvreux and Maxim Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Truffle Capital is recognized as a leading European venture capital firm.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investments are made in innovative life science companies globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Neovacs
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Neovacs
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neovacs Comparisons
Competitors of Neovacs
Neovacs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Altimmune, Vaxart, Allergy Therapeutics and Medicago, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for treating multiple infectious diseases
|
|
| domain | founded_year | HQ Location |
Aluminum-free allergy vaccines and diagnostics are developed for treatment.
|
|
| domain | founded_year | HQ Location |
Developer of vaccines to treat pandemic and seasonal influenza
|
|
| domain | founded_year | HQ Location |
Developer of vaccines for the treatment of infectious diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neovacs
Frequently Asked Questions about Neovacs
When was Neovacs founded?
Neovacs was founded in 1993 and raised its 1st funding round 14 years after it was founded.
Where is Neovacs located?
Neovacs is headquartered in Paris, France.
Who is the current CEO of Neovacs?
Hugo Brugiere is the current CEO of Neovacs.
Is Neovacs a funded company?
Neovacs is a funded company, having raised a total of $17.91M across 10 funding rounds to date. The company's 1st funding round was a Post-IPO of $9.1M, raised on Jul 18, 2007.
What does Neovacs do?
Neovacs was established in 1993 in Paris, France, as a contract development and manufacturing organization in the biotechnology sector. Vaccine production processes are handled, including formulation and scaling for clinical and commercial needs. Operations are centered in Europe, with expertise applied to various vaccine types. Leadership is provided by CEO Hugo Brugiere, overseeing facilities compliant with regulatory standards.
Who are the top competitors of Neovacs?
Neovacs's top competitors include Biological E, Vaxart and Allergy Therapeutics.
What products or services does Neovacs offer?
Neovacs offers Kinoide.
Who are Neovacs's investors?
Neovacs has 6 investors. Key investors include Debiopharm, Kepler Cheuvreux, Maxim Group, Truffle Capital, and APICAP.